TECHNOLOGYJun 9 · 12:10 UTCMIT TECHNOLOGY REVIEWThomas Macaulay

The Download: whole-body rejuvenation drugs and five things to know about AI

David Sinclair plans to test whole-body rejuvenation drugs in a $101 million XPrize competition aiming to reverse aging through human trials. The article also covers AI developments, including OpenAI's confidential IPO filing and U.S.-China tech tensions involving companies like BYD and Baidu.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

David SinclairpersonXPrize FoundationorganizationOpenAIorganizationBYDorganizationBaiduorganizationAlibabaorganizationAItopicrejuvenation drugstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

SCIENCEJun 9 · 10:00 UTC
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
HEALTHMay 28 · 13:26 UTC
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
HEALTHApr 9 · 00:00 UTC
Daily briefing: A treatment to reverse cellular ageing is about to be tested in people
HEALTHApr 25 · 20:38 UTC
Joe Rogan is promoting a new treatment that promises to reverse aging. It's booming among the elite... but side effects can be devastating: JILLIAN MICHAELS
HEALTHJun 9 · 10:00 UTC
The first-ever reverse-aging drug was just injected into a human
HEALTHJun 7 · 21:28 UTC
Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics